Welcome to our dedicated page for Ispecimen SEC filings (Ticker: ISPC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
iSpecimen Inc. filings document material events, governance matters, capital-structure changes, and reporting status for the company’s Nasdaq-listed common stock. Recent 8-K disclosures cover the completed 1-for-40 reverse stock split, related certificate amendments, Regulation FD press-release exhibits, shareholder meeting adjournments, and board composition changes.
The company’s regulatory record also includes emerging growth company disclosures and a Rule 12b-25 notice tied to its annual report filing process. These filings provide formal records of iSpecimen’s public-company obligations alongside its biospecimen marketplace operations.
iSpecimen Inc. (Nasdaq: ISPC) has filed Amendment No. 3 to its Form S-1 registration statement, signaling a forthcoming underwritten public offering of common stock and pre-funded warrants. The company plans to sell an unspecified number of shares and, for investors whose post-offering ownership would otherwise exceed 4.99% (optionally 9.99%), an equivalent number of pre-funded warrants priced at the offering price minus $0.0001 with a de-minimis $0.0001 exercise price. Both securities will be issued in a single closing on a firm-commitment basis led by WestPark Capital.
Key structural details:
- The final share count, public offering price, and gross proceeds will be determined at pricing; blanks remain in the filing.
- The company is a non-accelerated filer, smaller reporting company, and emerging growth company.
- Underwriter compensation includes customary cash fees plus up to $110,000 in reimbursable legal and out-of-pocket expenses.
- No listing is planned for the pre-funded warrants, limiting their secondary-market liquidity.
The filing emphasizes that the prospectus is preliminary, forward-looking statements are subject to risk, and no sales can occur until the SEC declares the registration effective.
iSpecimen announced significant changes to its Board of Directors on June 18, 2025. Richard J. Paolone (Chairman since February 2025) and John L. Brooks III (board member since June 2021) have resigned from the Board, effective immediately. Neither resignation involved disagreements with the company's operations, policies, or practices.
The Board appointed Anthony Lau as a new director on June 20, 2025. Lau brings significant experience as:
- CEO and CFO of Remington Resources (CSE-listed company) since 2021
- Expert in corporate governance and public company compliance
- Engineering professional in oil and gas infrastructure since 2014
Following these changes, the Board committees were restructured:
- Audit Committee: Lau (Chair), Dhaliwal, Yang
- Compensation Committee: Yang (Chair), Lau, Dhaliwal
- Nominating and Corporate Governance Committee: Dhaliwal (Chair), Yang, Lau